Clinical trial
Treatment for Patients With Metastatic Thyroid Cancer
NCT00176748 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00176748 |
|---|---|
| Title | Treatment for Patients With Metastatic Thyroid Cancer |
| Official title | Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131I Treatment |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thyroid Cancer |
| Intervention type | Drug |
| Interventions | AG 6013736 |
| Enrollment | 3 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Jun 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Jan 15, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: